Day One Biopharmaceuticals (NASDAQ: DAWN)
$14.92
(12.9%)
$1.71
Price as of April 26, 2024, 4:00 p.m. ET
Day One Biopharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Day One Biopharmaceuticals Company Info
Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in Brisbane, CA.
News & Analysis
Featured Article
Why Shares of Day One Pharmaceuticals Are Up Monday
The clinical-stage biotech released early trial news regarding its lead therapy candidate.
Jim Halley | Jun 5, 2023
Featured Article
Here's How Day One Biopharmaceuticals Stock Could Keep Climbing
A giant run-up on Monday could be the beginning of a much larger bull run.
Cory Renauer | Jun 15, 2022
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.